Recent publications published by researchers at the MRC WIMM.
Redefining the topology of the human bone marrow using augmented spatial transcriptomic analysis
Cooper RA. et al, (2025)
Investigation and management of thrombocytosis without JAK2, CALR or MPL mutations: A British Society for Haematology Guideline.
Godfrey AL. et al, (2025), Br J Haematol
Causal relevance of clonal haematopoiesis with cardiac disease and adverse remodelling: a Mendelian randomisation study.
Morley AP. et al, (2025), Open Heart, 12
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA.
Murphy L. et al, (2025), Science, 389
SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.
Cho H-J. et al, (2025), EMBO Mol Med, 17, 2115 - 2136
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.
Wang Z. et al, (2025), Blood, 146, 341 - 355
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A.
Brierley CK. et al, (2025), Nat Genet, 57, 1478 - 1492
HIGH PREVALENCE OF GERMLINE PREDISPOSITION IN PAEDIATRIC MYELODYSPLASTIC SYNDROME: A SINGLE-CENTRE RETROSPECTIVE ANALYSIS
Nyiro J. et al, (2025), EJC PAEDIATRIC ONCOLOGY, 6
Multi-endpoint AI morphology model (MEAM) enhances risk prediction for vascular events and disease progression in MPNs
Hu X. et al, (2025), BLOOD, 146, 5599 - 5600
Molecular profiling in MPN: who should have it and why?
Chee A. and Mead AJ., (2024), Hematology Am Soc Hematol Educ Program, 2024, 524 - 534
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary.
Harrison CN. et al, (2024), Future Oncol, 20, 3365 - 3376
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.
Li R. et al, (2024), Sci Transl Med, 16
Clinical utility of investigations in triple-negative thrombocytosis: A real-world, multicentre evaluation of UK practice.
Godfrey AL. et al, (2024), Br J Haematol, 205, 1411 - 1416
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Gerds AT. et al, (2024), Blood Adv, 8, 4511 - 4522
Predictive Performance of Cardiovascular Risk Scores in Cancer Survivors From the UK Biobank.
McCracken C. et al, (2024), JACC CardioOncol, 6, 575 - 588
Alternative platelet differentiation pathways initiated by nonhierarchically related hematopoietic stem cells.
Carrelha J. et al, (2024), Nat Immunol, 25, 1007 - 1019